Drakeford, Clive
Aguila, Sonia http://orcid.org/0000-0001-5794-5177
Roche, Fiona
Hokamp, Karsten http://orcid.org/0000-0001-7464-2370
Fazavana, Judicael
Cervantes, Mariana P.
Curtis, Annie M. http://orcid.org/0000-0002-9601-9624
Hawerkamp, Heike C.
Dhami, Sukhraj Pal Singh
Charles-Messance, Hugo
Hackett, Emer E.
Chion, Alain
Ward, Soracha
Ahmad, Azaz
Schoen, Ingmar http://orcid.org/0000-0002-5699-1160
Breen, Eamon
Keane, Joe
Murphy, Ross
Preston, Roger J. S.
O’Sullivan, Jamie M.
Sheedy, Frederick J.
Fallon, Padraic http://orcid.org/0000-0002-8401-7293
O’Donnell, James S.
Funding for this research was provided by:
Science Foundation Ireland (20/FFP-A/8952)
Foundation for the National Institutes of Health (HL081588)
Health Research Board (ILP-POR-2017-008)
Article History
Received: 24 July 2020
Accepted: 30 September 2022
First Online: 3 November 2022
Competing interests
: J.S.O’D. has served on the speaker’s bureau for Baxter, Bayer, Novo Nordisk, Boehringer Ingelheim, Leo Pharma, Takeda and Octapharma. He has also served on the advisory boards of Baxter, Bayer, Octapharma CSL Behring, Daiichi Sankyo, Boehringer Ingelheim, Takeda and Pfizer. J.S.O’D. has also received research grant funding awards from 3 M, Baxter, Bayer, Pfizer, Shire, Takeda and Novo Nordisk. The remaining authors declare no competing interests